<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBM</journal-id><journal-title-group><journal-title>Journal of Biosciences and Medicines</journal-title></journal-title-group><issn pub-type="epub">2327-5081</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbm.2016.41014</article-id><article-id pub-id-type="publisher-id">JBM-63017</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Design, Synthesize and Bio-Evaluate 1,2-Dihydroisoquinolin-3(4&lt;i&gt;H&lt;/i&gt;)-One Derivates as Acetylcholinesterase and &lt;i&gt;β&lt;/i&gt;-Secretase Dual Inhibitors in Treatment with Alzheimer’s Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>ouchao</surname><given-names>Deng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yuren</surname><given-names>Jiang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xiongjie</surname><given-names>Zhao</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jinlian</surname><given-names>Wang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Pharmaceutical Engineering, College of Chemistry and Chemical Engineering, Central South University, Changsha, China</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>jiangyr@mail.csu.edu.cn(YJ)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>12</month><year>2015</year></pub-date><volume>04</volume><issue>01</issue><fpage>112</fpage><lpage>123</lpage><history><date date-type="received"><day>24</day>	<month>November</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>23</month>	<year>January</year>	</date><date date-type="accepted"><day>26</day>	<month>January</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  With the recent research advances in molecular biology and technology, many credible hypothe-ses about the progress of Alzheimer’s disease (AD) have been proposed, among which the amyloid and cholinergic hypotheses are commonly used to develop reliable therapeutic agents. The multitarget-directed ligand (MTDL) approach was taken in this work to develop multi-functional agents, which can mainly serve as dual BACE 1 and AChE inhibitors. Depending on the scaffolds of (+)-(S)- dihydro-ar-tumerone and (－)-gallocatechin gallate, 3 series of new compounds have been designed, synthesized and evaluated, from which we have identified 2-(2-(3-methylbenzoyl)-3-oxo-1,2,3,4- tetrahydroisoquinolin-6-yl) isoindoline-1,3-dione (3d) as a new cholinesterase and 
  <em>β</em>-secretase dual inhibitor without toxicity. Furthermore, 3d also exhibits hydrogen peroxide scavenging activity which could help to reduce the reactive oxygen species (ROS) in the brain of AD patients.
 
</p></abstract><kwd-group><kwd>&lt;i&gt;β&lt;/i&gt;-Secretase (BACE 1)</kwd><kwd> Acetylcholinesterase (AChE)</kwd><kwd> Inhibitor</kwd><kwd> Alzheimer’s Disease (AD)</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Alzheimer’s disease (AD), one of the most common forms of dementia, is a progressive and neurodegenerative brain disorder that targets to cholinergic neurons of central nervous system (CNS) accompanied with spatial awareness and cognitive ability [<xref ref-type="bibr" rid="scirp.63017-ref1">1</xref>] . The risk of suffering this pathology increases sharply with age. However, the pathological beginning and advancement of AD are greatly complication.</p><p>Considering that the pathological beginning and advancement of AD are greatly complication and multi- factors effected, a single drug acting on a specific target to acquire the desired clinical effects might not be much effective [<xref ref-type="bibr" rid="scirp.63017-ref2">2</xref>] . Accordingly, the multitarget-directed ligand (MTDL) approach [<xref ref-type="bibr" rid="scirp.63017-ref3">3</xref>] has been increasingly investigated by many researchers, which have designed a lot of various compounds aiming to different targets by making use of this approach. In order to design effective dual inhibitors targeting to BACE 1 and AChE for the treatment of AD, the MTDL approach was also taken in this work.</p><p>As reported [<xref ref-type="bibr" rid="scirp.63017-ref4">4</xref>] , (−)-gallocatechin gallate (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>) isolated from green tea, Camellia sinensis L., is a potent naturally occurring β-secretase (BACE 1) inhibitor. There are also several SAR studies [<xref ref-type="bibr" rid="scirp.63017-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.63017-ref5">5</xref>] analyz- ing the relationship between the structure of (−)-gallocatechin gallate and its inhibitory activity to BACE 1, which are greatly useful when starting a project to research novel BACE 1 inhibitors especially based the structure of the lead compound, (−)-gallocatechin gallate. From the SAR studies, the O-gallate moiety of (−)-gallocatechin gallate, which forms not strong interactions with BACE 1, was clipped from the original structure of (−)-gallo- catechin gallate when developing the scaffold in this work. On the contrary, the aromatic ring connected to C-2 of the structure of (−)-gallocatechin gallate is an important factor to BACE 1 inhibitory activity and therefore was kept. Meanwhile, (+)-(S)-dihydro-ar-tumerone (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>) isolated from P. dasyrachis oil, was proved to be a potent AChE inhibitor possessing neuroprotective effects. And more interestingly, (+)-(S)-dihydro- ar-tumerone has a highly similar structure with (−)-gallocatechin gallate especially when they were superimposed together in a 3D model (<xref ref-type="fig" rid="fig1">Figure 1</xref>) by making use of Molecular Operating Environment (MOE 2008.10), which means that both BACE 1 and AChE inhibitors could have similar main structures at some degree.</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> The scaffolds of (+)-(s)-dihydro-ar-tuerone and (−)-gallo- catechin gallate (its’ gallate group was clipped) which were superim- posed together in a 3D model by using MOE 2008.10</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/14-2150149x7.png"/></fig><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> The design of 3 series of new derivates was based on the molecular skeleton, 6-amino-1,2-dihydroisoquinolin-3(4H)-one, which was generated from the 3D structures of compound (+)-(S)-dihydro- ar-tumerone and (−)-gallocatechin gallate by making use of Molecu- lar Operating Environment (MOE 2008.10). The substitutions R were acyl groups which were described in <xref ref-type="table" rid="table1">Table 1</xref></title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/14-2150149x8.png"/></fig><p>Then, a new molecular skeleton, tetrahydroisoquinolin-3-one fitting the common structure of the scaffolds of (+)-(S)-dihydro-ar-tumerone and (−)-gallocatechin gallate, was proposed, which aimed to design BACE 1 and AChE dual inhibitors by making use of Molecular Operating Environment (MOE 2008.10). At last, series of derivates based on this molecular skeleton was synthesized and its biological activity was evaluated.</p><p>As depicted in <xref ref-type="fig" rid="fig2">Figure 2</xref>, the designed new molecules are divided into 3 series on the basis of the mainly structural differences between them. Firstly, there is an absence of nitrogen atom at 6-benzene position in the compounds of series 1. So, the contribution of nitrogen atom or the group connected nitrogen atom at 6-benzene position to enhance binding affinity will be revealed with such structural difference. Secondly, the existing of an aromatic group at the nitrogen atom of 6-benzene position in the structure of the compounds of series 3, especially comparing to the compounds in series 2, will help to understand whether the aromatic group can form π-π force with the residues of the pockets of enzymes. Lastly, there are also simple functional changes at N-2 in the structure of the compounds of series 1, 3 and 5. Noticeable, most of substitutions are aromatic groups; because the pharmacophore analysis indicated that an aromatic ring at these positions is essential to bind BACE 1.</p></sec><sec id="s2"><title>2. Results and Discussion</title><sec id="s2_1"><title>2.1. Chemistry</title><p>The synthesis of the 3 series of new molecules (Scheme 1) had been processed by standard or reported methods, in very efficient and short synthetic sequences, with good overall yields. All new molecules gave satisfactory analytical and spectroscopic data, in good agreement with their structures.</p></sec><sec id="s2_2"><title>2.2. AChE Inhibition</title><p>The AChE inhibitory activities of the new molecules were assayed using a modified version of the Ellman protocol in vitro [<xref ref-type="bibr" rid="scirp.63017-ref6">6</xref>] . In <xref ref-type="table" rid="table1">Table 1</xref>, the IC<sub>50</sub> values of AChE inhibition were reported by using donepezil as control. All synthesized compounds possessed moderate to potent AChE inhibition (IC<sub>50</sub> values ranging from 1 nM to 1000 nM) and several derivates had equipotent AChE inhibition with donepezil. From <xref ref-type="table" rid="table1">Table 1</xref>, it was obviously to find that there was an averagely inhibitory activity enhancement among 3 series (series 3 &gt; series 2 &gt; series 1). And the relevant docking studies (AchE, PDB ID: 4EY7) revealed that the N-phthaloyl in the compounds of series 3 can help them form a strong π-π force with the residues of the pocket which made the main contributions to their potent AChE inhibition (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><disp-formula id="scirp.63017-formula1040"><graphic  xlink:href="http://html.scirp.org/file/14-2150149x9.png"  xlink:type="simple"/></disp-formula><p>Scheme 1. Reagents and conditions: (a) HCO<sub>2</sub>H, H<sub>2</sub>O<sub>2</sub>, H<sub>2</sub>O, 2 h, 40˚C, 7 h, rt; (b) HCl, NaN<sub>3</sub>, H<sub>2</sub>O, 0˚C; 2 h, 0˚C; 0˚C to 25˚C; overnight, 25˚C; K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, cooled, pH 9; (c) HNO<sub>3</sub>, −25˚C; (d) Zn, CH<sub>3</sub>COOH, THF; (e) AC<sub>2</sub>O, CH<sub>3</sub>COOH; (f) Various acyl chloride, anhydrous DMA, 0˚C - 100˚C and stirring for 4 h.</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> AChE and BACE 1 inhibition activity for all synthesized compounds</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Compound</th><th align="center" valign="middle"  rowspan="2"  >R</th><th align="center" valign="middle"  colspan="2"  >IC<sub>50</sub> &#177; SD<sup>a</sup></th></tr></thead><tr><td align="center" valign="middle" >AChE (nM)</td><td align="center" valign="middle" >BACE 1 (&#181;M)</td></tr><tr><td align="center" valign="middle" >1b</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x11.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >634.3 &#177; 32.5</td><td align="center" valign="middle" >174.82 &#177; 8.93</td></tr><tr><td align="center" valign="middle" >1c</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x12.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >528.9 &#177; 27.6</td><td align="center" valign="middle" >130.08 &#177; 7.5</td></tr><tr><td align="center" valign="middle" >1d</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x13.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >433.7 &#177; 24.7</td><td align="center" valign="middle" >73.2 &#177; 3.32</td></tr><tr><td align="center" valign="middle" >1f</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x14.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >462.6 &#177; 27.3</td><td align="center" valign="middle" >78.75 &#177; 3.74</td></tr><tr><td align="center" valign="middle" >1g</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x15.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >375.4 &#177; 21.8</td><td align="center" valign="middle" >131.46 &#177; 8.73</td></tr><tr><td align="center" valign="middle" >2b</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x16.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >248.31 &#177; 14.42</td><td align="center" valign="middle" >68.79 &#177; 3.84</td></tr><tr><td align="center" valign="middle" >2c</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x17.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >238.23 &#177; 13.91</td><td align="center" valign="middle" >60.59 &#177; 5.73</td></tr><tr><td align="center" valign="middle" >2d</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x18.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >211.84 &#177; 13.59</td><td align="center" valign="middle" >37.96 &#177; 2.31</td></tr><tr><td align="center" valign="middle" >2e</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x19.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >323.59 &#177; 18.18</td><td align="center" valign="middle" >40.72 &#177; 2.73</td></tr><tr><td align="center" valign="middle" >2f</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x20.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >263.03 &#177; 16.15</td><td align="center" valign="middle" >28.22 &#177; 1.64</td></tr><tr><td align="center" valign="middle" >2g</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x21.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >246.04 &#177; 14.3</td><td align="center" valign="middle" >35.06 &#177; 2.53</td></tr><tr><td align="center" valign="middle" >2j</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x22.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >223.87 &#177; 13.19</td><td align="center" valign="middle" >22.24 &#177; 2.16</td></tr><tr><td align="center" valign="middle" >2k</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x23.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >357.27 &#177; 19.86</td><td align="center" valign="middle" >21.46 &#177; 1.26</td></tr><tr><td align="center" valign="middle" >3b</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x24.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >74.44 &#177; 5.72</td><td align="center" valign="middle" >47.18 &#177; 3.58</td></tr><tr><td align="center" valign="middle" >3c</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x25.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >65.6 &#177; 4.28</td><td align="center" valign="middle" >5.87 &#177; 0.34</td></tr><tr><td align="center" valign="middle" >3d</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x26.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >25.48 &#177; 1.85</td><td align="center" valign="middle" >4.45 &#177; 0.32</td></tr><tr><td align="center" valign="middle" >3f</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x27.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >81.65 &#177; 9.1</td><td align="center" valign="middle" >2.96 &#177; 0.27</td></tr><tr><td align="center" valign="middle" >3g</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x28.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >76.56 &#177; 5.63</td><td align="center" valign="middle" >8.49 &#177; 0.56</td></tr><tr><td align="center" valign="middle" >3h</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x29.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >81.85 &#177; 4.13</td><td align="center" valign="middle" >1.69 &#177; 0.09</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >3j</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x30.png" xlink:type="simple"/></inline-formula></th><th align="center" valign="middle" >55.26 &#177; 5.85</th><th align="center" valign="middle" >2.07 &#177; 0.17</th></tr></thead><tr><td align="center" valign="middle" >3k</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/14-2150149x31.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >86.7 &#177; 6.34</td><td align="center" valign="middle" >15.65 &#177; 0.84</td></tr><tr><td align="center" valign="middle" >Donepezil</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >15.27 &#177; 0.78</td><td align="center" valign="middle" >122.93 &#177; 13.27</td></tr></tbody></table></table-wrap></table-wrap-group><p><sup>a</sup>The in vitro test compound concentration required to produce 50% inhibition of AChE and BACE 1. The result (IC<sub>50</sub>) was the mean of three independent experiments.</p><fig-group id="fig3"><label><xref ref-type="fig" rid="fig3">Figure 3</xref></label><caption><title> Compound 3d docked with the pocket of AChE (a) the 3D model of this complex and (b) the force interactions between compound 3d and the residues of AChE in a 2D model.</title></caption><fig id ="fig3_1"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/14-2150149x33.png"/></fig><fig id ="fig3_2"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/14-2150149x32.png"/></fig></fig-group></sec><sec id="s2_3"><title>2.3. β-Secretase Inhibition</title><p>The BACE 1 inhibitory activities of all synthesized compounds were tested using FRET (Fluorescence resonance energy transfer) method [<xref ref-type="bibr" rid="scirp.63017-ref7">7</xref>] based on the β-secretase Inhibitor Screening Assay Kit (Shanghai Haling biological technological CO., LTD., China). In <xref ref-type="table" rid="table1">Table 1</xref>, compounds containing a nitrogen atom at C-6 position of series 2 and 3 displayed more potency than those series not containing. Furthermore, compounds in series 3 also possessed more strongly inhibitory activities than those in series 1 and 2. Compound 3d was taken as an example of compounds in series 3 to do the docking studies (BACE 1, PDB ID: 1M4H), and the force interactions between 3d and the active sites of BACE 1 were described in 2D and 3D model (<xref ref-type="fig" rid="fig4">Figure 4</xref>). In <xref ref-type="fig" rid="fig4">Figure 4</xref>, compound 3d had an arene-cation interaction with Arg 128 which belongs to the S3’ sub-pocket of BACE 1 and can also form hydrogen bonds with Asp 32 (belongs to the catalytic sites), Arg 235 (belongs to the S2 sub-pocket) and Thr 72 (belongs to the S2 sub-pocket).</p></sec><sec id="s2_4"><title>2.4. Hydrogen Peroxide Scavenging Activity</title><p>In order to further evaluate the antioxidant activity of the synthesized derivatives, compounds 1d, 2e, 2j, 3d and 3f were analyzed using the ferrous ion oxidation-xylenol orange (FOX) assay [<xref ref-type="bibr" rid="scirp.63017-ref8">8</xref>] . The results shown in <xref ref-type="fig" rid="fig5">Figure 5</xref> demonstrate that 1d, 2e, 2j, 3d and 3f possess obvious scavenging activities for hydrogen peroxide at the slightly high concentrations, while the scavenging activities are not noticeable as the compounds concentration less than 100 μM. Meanwhile, the results indicate that 1d, 2e, 2j, 3d and 3f almost have the same hydrogen peroxide scavenging activity on different concentrations.</p></sec><sec id="s2_5"><title>2.5. Cytotoxicity Assay</title><p>The CCK-8 assay [<xref ref-type="bibr" rid="scirp.63017-ref9">9</xref>] was taken in this work to test the cytotoxicity of compound 1d, 2e, 2j, 3d and 3f on HEK 293 cells. And compound 1d, 2e, 2j, 3d and 3f was tested in five different concentrations (1, 10, 50, 100, and 200 μM in final concentration) respectively. The values in <xref ref-type="fig" rid="fig6">Figure 6</xref> demonstrate that all these tested compounds do not show obvious toxicity in the CCK-8 assay, suggesting that 1d, 2e, 2j, 3d and 3f lack general toxicity.</p><fig-group id="fig4"><label><xref ref-type="fig" rid="fig4">Figure 4</xref></label><caption><title> A representation of molecular docking derived binding pose (3D) of compound 3d in the active site of BACE-1 (a) and docking simulated binding mode (2D) of compound 3d bound in the active site of BACE-1 (b).</title></caption><fig id ="fig4_1"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/14-2150149x35.png"/></fig><fig id ="fig4_2"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/14-2150149x34.png"/></fig></fig-group><fig id="fig5"  position="float"><label><xref ref-type="fig" rid="fig5">Figure 5</xref></label><caption><title> Scavenging effect of 1d, 2e, 2j, 3d and 3f on hydrogen peroxide, which determined by the FOX assay with slight change. The results reported are the mean &#177; SD of three independent experiments</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/14-2150149x36.png"/></fig><fig id="fig6"  position="float"><label><xref ref-type="fig" rid="fig6">Figure 6</xref></label><caption><title> The cell viability of compound 1d, 2e, 2j, 3d and 3f on HEK 293 cells using CCK-8 assay kits. The results reported are the mean &#177; SD of three independent experiments</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/14-2150149x37.png"/></fig></sec></sec><sec id="s3"><title>3. Experimental Procedures</title><p>All chemical reagents in this work were commercially available and solvents were dried in standard methods before using. Melting points were determined on an X4 melting point apparatus (Beijing Tech Instrument CO., LTD., China) and were uncorrected. <sup>1</sup>H NMR spectra were recorded on a BRUKER 500 MHz or 400 MHz spectrometer with TMS as the internal reference. Reactions were monitored by thin-layer chromatography (TLC) on Merck (0.25 mm) glass-packed precoated silica gel plates (60 F<sub>254</sub>) and column chromatography was performed on silica Gel 60 (230 mesh). The purity of the synthesized compounds was determined by HPLC system (HP 1100 series, Agilent Technologies, Palo Alto, USA) and their final purity was all above 95%. MS spectra were recorded on Waters ZQ 4000 apparatus (electrospray ionization, ESI).</p><sec id="s3_1"><title>3.1. Synthesis Section</title><p>The procedure for synthesis of 1H-inden-2(3H)-one (2) [<xref ref-type="bibr" rid="scirp.63017-ref10">10</xref>]</p><p>To a three-necked flask hydrogen peroxide (7 ml, 30%) and formic acid (35 ml, 88%) were added, then a dropping funnel, stirrer and thermometer were put on its necks. When thetemperature was stabilized at 40˚C, indene (compound 1, 11.7 ml) was added using dropping funnel, with stirring overa period of 3 h. The reaction mixture was kept stirring at 40˚C for another 7 h. A yellowishbrown crystalline solid was obtained after removing the excess formic acid underreduced pressure. To a tow-necked flask equipped with a condenser sulfuric acid (100 ml, 7%) was added, and after the solution was heated to boiling, the obtained solid was added over several times. The mixture was steamdistilled and the steam was cooled and gathered. The gathered solution was further cold at 10˚C over a night and then filtered, to generate white crystals. Compound 2 was obtained after the white crystals were further dried in a vacuum under room temperature over 24 h. The yield is 60% - 75%, mp 56˚C - 58˚C (lit [<xref ref-type="bibr" rid="scirp.63017-ref11">11</xref>] , 54˚C - 56˚C).</p><p>The procedure for synthesis of 1,2-dihydroisoquinolin-3(4H)-one (3) [<xref ref-type="bibr" rid="scirp.63017-ref12">12</xref>]</p><p>In an ice-cooled solution of Compound 2 (2.0 g, 15.1 mmol, 1.0 equiv) in concentrated HCl (50 mL), NaN<sub>3</sub> (2.0 g, 30.1 mmol, 2.0 equiv) was added portionwise. The reaction mixture was kept stirring for 2 h at 0˚C, then slowly warmed to room temperature and kept stirring for a night. After the mixture was quenched with ice water (50 mL) and basified to pH 9 using K<sub>2</sub>CO<sub>3</sub>, the solution was extracted with CH<sub>2</sub>Cl<sub>2</sub>. Next, the organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated, to give a crude yellow solid which was further purified by flash chromatography on silica gel (hexane/EtOAc: 1/1 to EtOAc). The purified compound 3 is a light yellow solid (1.45 g, 65% yield), mp 143˚C - 145˚C (lit [<xref ref-type="bibr" rid="scirp.63017-ref13">13</xref>] , 146˚C - 148˚C).</p><p>The procedure for synthesis of 5-nitro-1H-inden-2(3H)-one (4) [<xref ref-type="bibr" rid="scirp.63017-ref14">14</xref>]</p><p>To a cold (−25˚C) concentrated nitric acid (16 mL, 90%), Compound 2 (1.4 mg, 10.0 mmol) was added portionwise with vigorous stirring. The mixture was stirred for another 30 min at −25˚C. Then the mixture was removed to 0˚C and stirred for another 1 h. Next, the reaction mixture was poured into a mixture of sodium hydroxide (13.0 g) in water and ice (ca. 100 mL), and extracted with ethyl acetate. The combined organic layer was washed with water, dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure, to give a crude yellow solid. Then the crude product was further purified by flash chromatography on silica gel (chloroform). The purified compound 4 is a yellow solid (1.02 g, 54% yield), mp 138˚C - 140˚C (lit. [<xref ref-type="bibr" rid="scirp.63017-ref14">14</xref>] , 141˚C - 143˚C).</p><p>The procedure for synthesis of 6-nitro-1,2-dihydroisoquinolin-3(4H)-one (5)</p><p>Compund 5 was synthesized as the procedure for synthesis of Compound 3. Compund 5 is a yellow solid, m.p: 159˚C - 161˚C, ESI-MS (m/z): 193 (M + H<sup>+</sup>), <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.19 - 8.11 (m, 2H), 7.38 (d, J = 8.4 Hz, 1H), 6.70 (s, 1H), 4.62 (s, 2H), 3.71 (s, 2H).</p><p>The procedure for synthesis of 6-amino-1,2-dihydroisoquinolin-3(4H)-one (6) [<xref ref-type="bibr" rid="scirp.63017-ref15">15</xref>]</p><p>In a solution of Zn (70 mmol) aerated with ethylic acid (3 mL, 50 mmol) in THF (40 mL), Compound 5 (2.0 g, 3.3 mmol) was added with vigorous stirring. The reaction mixture was kept stirring for 12 h, under the protection of N<sub>2</sub> at 65˚C. Then the mixture was filtered and the solvent was removed under reduced pressure. Next, the obtained residue was further washed by 5% NaOH (30 mL) to generate a crude brown solid. Then the crude product was further purified by flash chromatography on silica gel (Ethyl acetate/glacial acetic acid, 150:2). The purified compound 6 is a brown solid (1.40 g, 83% yield), mp 153˚C - 155˚C. ESI-MS (m/z): 163 (M + H<sup>+</sup>), <sup>1</sup>H NMR (500 MHz, DMSO) δ 7.89 (d, J = 19.9 Hz, 1H), 6.83 (dd, J = 29.7, 8.0 Hz, 1H), 6.45 - 6.37 (m, 1H), 6.33 (s, 1H), 4.89 (d, J = 11.3 Hz, 2H), 4.16 (s, 2H), 3.25 (d, J = 15.8 Hz, 2H).</p><p>The general procedure for synthesis of N-(3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)acetamide (7) [<xref ref-type="bibr" rid="scirp.63017-ref16">16</xref>]</p><p>Compound 6 (1.22 g, 7.5 mmol) was added to a solution of acetic anhydride (10 mL) and the reaction was kept at room temperature for 5 h. Then the mixture was poured into ice water. The precipitate was filtered, washed with water, and dried to give the compound 7 (1.27 g, 83%), m.p. 89˚C - 91˚C. ESI-MS (m/z): 205 (M + H<sup>+</sup>), <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.48 (d, J = 8.4 Hz, 2H), 7.39 (s, 1H), 7.26 (s, 1H), 6.46 (s, 1H), 4.73 (s, 2H), 3.79 (d, J = 5.8 Hz, 2H), 2.19 (s, 3H).</p><p>The general procedure for synthesis of 2-(3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)isoindoline-1,3-dione (8) [<xref ref-type="bibr" rid="scirp.63017-ref16">16</xref>]</p><p>Compound 6 (1.22 g, 7.5 mmol) was added to a solution of phthalic anhydride (2.25 g, 15.0 mmol) in acetic acid (25 ml) and the reaction was kept at 100˚C for 1 h. Then the mixture was poured into ice water. The precipitate was filtered, washed with water, and dried to give the compound 8 (1.91 g, 87%), m.p. 207˚C - 209˚C. ESI-MS (m/z): 293 (M + H<sup>+</sup>), <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.99 (dd, J = 5.5, 2.9 Hz, 2H), 7.83 (dd, J = 5.5, 3.0 Hz, 2H), 7.47 (s, 3H), 6.47 (s, 1H), 4.76 (s, 2H), 3.60 (d, J = 5.9 Hz, 2H).</p><p>The general procedure for synthesis of series 1, 2 and 3 [<xref ref-type="bibr" rid="scirp.63017-ref17">17</xref>]</p><p>To a solution of compound 3 (compound 7 or compound 8, 1.0 mmol) in anhydrous dioxane (5 ml), 4-dime- thylaminepyridine (10 mg) and anhydrous potassium carbonate (100 mg) was added at room temperature. Then different kinds of acyl chloride (1.5 mmol) was added respectively and the mixture was kept stirring at reflux for 0.5 to 3 h. Next, after the solution was cooled to 0˚C, HCl (5%) was added to change the solution to pH 1 and extracted by chloroform. The organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated, to give the relevant crude product which was further purified by flash chromatography on silica gel.</p><p>2-acetyl-1,2-dihydroisoquinolin-3(4H)-one (1b)</p><p>Compound 1b was found to be yellowish oil, yield 43%. ESI-MS (m/z): 190 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.34 (t, J = 6.1 Hz, 2H), 7.29 (d, J = 6.8 Hz, 2H), 4.60 (d, J = 3.6 Hz, 2H), 3.83 - 3.76 (m, 2H), 2.13 (d, J = 2.1 Hz, 3H).</p><p>2-benzoyl-1,2-dihydroisoquinolin-3(4H)-one (1c)</p><p>Compound 1c was found to be orange oil, yield 45%. ESI-MS (m/z): 252 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.30 (d, J = 7.2 Hz, 2H), 7.22 (s, 5H), 7.19 - 7.13 (m, 2H), 4.62 (s, 2H), 3.72 (d, J = 5.8 Hz, 2H).</p><p>2-(3-methylbenzoyl)-1,2-dihydroisoquinolin-3(4H)-one (1d)</p><p>Compound 1d was found to be sandy-brown oil, yield 47%. ESI-MS (m/z): 266 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 7.84 (d, J = 7.8 Hz, 2H), 7.43 (t, J = 7.7 Hz, 1H), 7.36 ? 7.30 (m, 2H), 7.25 (dd, J = 15.4, 6.9 Hz, 3H), 4.78 (s, 2H), 3.63 (d, J = 6.0 Hz, 2H), 2.39 (s, 3H).</p><p>2-(2-methoxybenzoyl)-1,2-dihydroisoquinolin-3(4H)-one (1f)</p><p>Compound 1f was found to be rufous oil, yield 42%. ESI-MS (m/z): 282 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.82 (dd, J = 7.7, 1.7 Hz, 1H), 7.50 - 7.43 (m, 1H), 7.34 (d, J = 6.5 Hz, 4H), 7.04 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 4.91 (s, 2H), 3.86 (d, J = 5.5 Hz, 2H), 3.43 (s, 3H).</p><p>2-(2-phenylacetyl)-1,2-dihydroisoquinolin-3(4H)-one (1g)</p><p>Compound 1g was found to be yellowish oil, yield 52%. ESI-MS (m/z): 266 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.32 (d, J = 7.2 Hz, 2H), 7.22 (s, 5H), 7.18 - 7.14 (m, 2H), 4.62 (s, 2H), 3.69 (s, 2H), 3.63 (d, J = 5.8 Hz, 2H).</p><p>N-(2-acetyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)acetamide (2b)</p><p>Compound 2b found to be yellowish oil, yield 43%. ESI-MS (m/z): 247 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 8.85 (s, 1H), 7.20 (d, J = 8.0 Hz, 2H), 7.09 (s, 1H), 4.25 (s, 2H), 3.38 (d, J = 5.8 Hz, 2H), 1.81 (d, J = 7.1 Hz, 6H).</p><p>N-(2-benzoyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)acetamide (2c)</p><p>Compound 2c was found to be orange solid, yield 45%. ESI-MS (m/z): 309 (M + H<sup>+</sup>), m.p. 151˚C - 153˚C. <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.67 (s, 1H), 7.46 (d, J = 8.3 Hz, 2H), 7.26 (s, 5H), 7.11 (s, 1H), 4.63 (s, 2H), 3.55 (d, J = 5.8 Hz, 2H), 2.19 (s, 3H).</p><p>N-(2-(3-methylbenzoyl)-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)acetamide (2d)</p><p>Compound 2d was found to be yellow solid, yield 48%. ESI-MS (m/z): 323 (M + H<sup>+</sup>), m.p. 135˚C - 137˚C. <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.87 (s, 1H), 7.48 (d, J = 6.7 Hz, 2H), 7.44 (d, J = 6.0 Hz, 1H), 7.37 (t, J = 6.1 Hz, 1H), 7.28 - 7.21 (m, 3H), 4.89 (s, 2H), 3.82 (d, J = 4.7 Hz, 2H), 2.43 (s, 3H), 2.19 (s, 3H).</p><p>N-(2-(3-chlorobenzoyl)-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)acetamide (2e)</p><p>Compound 2e was found to be yellow solid, yield 42%. ESI-MS (m/z): 343 (M + H<sup>+</sup>), m.p. 143˚C - 145˚C. <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.51 - 7.43 (m, 2H), 7.31 - 7.29 (m, 1H), 7.27 (d, J = 2.3 Hz, 1H), 7.24 - 7.18 (m, 2H), 7.15 (t, J = 6.7 Hz, 2H), 4.64 (s, 2H), 3.66 (s, 2H), 2.29 - 2.09 (m, 3H).</p><p>N-(2-(2-methoxybenzoyl)-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)acetamide (2f)</p><p>Compound 2f was found to be light brown solid, yield 44%. ESI-MS (m/z): 339 (M + H<sup>+</sup>), m.p. 117˚C - 119˚C. <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 8.10 (d, J = 7.4 Hz, 1H), 7.83 (dd, J = 7.7, 1.8 Hz, 1H), 7.51 (t, J = 7.9 Hz, 3H), 7.27 - 7.23 (m, 1H), 7.03 (t, J = 7.6 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 4.88 (s, 2H), 3.79 (d, J = 5.6 Hz, 2H), 3.51 (s, 3H), 2.16 (s, 3H).</p><p>N-(3-oxo-2-(2-phenylacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)acetamide (2g)</p><p>Compound 4g was found to be yellowish oil, yield 48%. ESI-MS (m/z): 323 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.62 (s, 1H), 7.46 (d, J = 8.3 Hz, 2H), 7.26 (s, 5H), 7.11 (s, 1H), 4.63 (s, 2H), 3.72 (s, 2H), 3.55 (d, J = 5.8 Hz, 2H), 2.19 (s, 3H).</p><p>N-(3-oxo-2-(3-phenylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)acetamide (2j)</p><p>Compound 2j was found to be light brown oil, yield 52%. ESI-MS (m/z): 337 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.65 (s, 1H), 7.45 (d, J = 6.5 Hz, 2H), 7.28 - 7.23 (m, 2H), 7.20 (d, J = 5.1 Hz, 3H), 7.16 (s, 1H), 4.59 (s, 2H), 3.64 (d, J = 4.7 Hz, 2H), 2.99 (t, J = 5.9 Hz, 2H), 2.77 (t, J = 6.0 Hz, 2H), 2.17 (s, 3H).</p><p>N-(2-nicotinoyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)acetamide (2k)</p><p>Compound 2k found to be light red solid, yield 47%. ESI-MS (m/z): 310 (M + H<sup>+</sup>), m.p. 168˚C - 170˚C. <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 9.24 (d, J = 2.1 Hz, 1H), 8.82 (dd, J = 4.9, 1.7 Hz, 1H), 8.33 (dt, J = 8.0, 1.9 Hz, 1H), 7.46 (d, J = 8.6 Hz, 3H), 7.40 (d, J = 8.4 Hz, 1H), 4.91 (s, 2H), 3.79 (d, J = 5.9 Hz, 2H), 2.17 (s, 3H).</p><p>2-(2-acetyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)isoindoline-1,3-dione (3b)</p><p>Compound 3b was found to be yellow solid, yield 45%. ESI-MS (m/z): 335 (M + H<sup>+</sup>), m.p. 135˚C - 137˚C. <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 8.01 - 7.96 (m, 2H), 7.83 (dd, J = 4.4, 2.4 Hz, 2H), 7.48 - 7.44 (m, 3H), 4.65 (s, 2H), 3.59 (d, J = 4.6 Hz, 2H), 2.19 (d, J = 0.6 Hz, 3H).</p><p>2-(2-benzoyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)isoindoline-1,3-dione (3c)</p><p>Compound 3c was found to be yellow solid, yield 43%. ESI-MS (m/z): 397 (M + H<sup>+</sup>), m.p. 196˚C - 198˚C. <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 8.08 (t, J = 1.5 Hz, 2H), 7.98 (dd, J = 5.5, 3.0 Hz, 2H), 7.83 (dd, J = 5.5, 3.1 Hz, 2H), 7.69 - 7.61 (m, 6H), 4.95 (s, 2H), 3.94 (d, J = 6.0 Hz, 2H).</p><p>2-(2-(3-methylbenzoyl)-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)isoindoline-1,3-dione (3d)</p><p>Compound 3d was found to be orange solid, yield 46%. ESI-MS (m/z): 411 (M + H<sup>+</sup>), m.p. 184˚C - 186˚C. <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.98 (dd, J = 4.5, 2.5 Hz, 2H), 7.91 - 7.86 (m, 2H), 7.82 (dd, J = 4.4, 2.5 Hz, 2H), 7.46 (q, J = 7.8, 7.2 Hz, 5H), 4.92 (s, 2H), 3.93 (d, J = 4.8 Hz, 2H), 2.44 (s, 3H).</p><p>2-(2-(2-methoxybenzoyl)-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)isoindoline-1,3-dione (3f)</p><p>Compound 3f was found to be brown solid, yield 42%. ESI-MS (m/z): 427 (M + H<sup>+</sup>), m.p. 157-159℃. <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.99 (dd, J = 5.5, 3.1 Hz, 2H), 7.84 (dd, J = 5.4, 3.1 Hz, 2H), 7.55 ? 7.50 (m, 3H), 7.48 - 7.44 (m, 3H), 7.06 (td, J = 7.5, 1.0 Hz, 1H), 4.93 (s, 2H), 3.93 (d, J = 5.5 Hz, 2H), 3.50 (s, 3H).</p><p>2-(3-oxo-2-(2-phenylacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)isoindoline-1,3-dione (3g)</p><p>Compound 3g was found to be orange oil, yield 42%. ESI-MS (m/z): 411 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 8.00 (dd, J = 5.5, 3.0 Hz, 2H), 7.84 (dd, J = 5.5, 3.1 Hz, 2H), 7.45 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 7.27 (s, 4H), 4.67 (s, 2H), 3.74 (s, 2H), 3.61 (d, J = 5.8 Hz, 2H).</p><p>2-(2-(2-(4-methoxyphenyl)acetyl)-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)isoindoline-1,3-dione (3h)</p><p>Compound 3h was found to be claybank oil, yield 47%. ESI-MS (m/z): 441 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.98 (dd, J = 4.5, 2.4 Hz, 2H), 7.83 (ddd, J = 4.4, 2.3, 1.2 Hz, 2H), 7.36 - 7.31 (m, 2H), 7.22 - 7.17 (m, 2H), 6.90 - 6.86 (m, 1H), 6.85 - 6.81 (m, 2H), 4.68 - 4.62 (m, 2H), 3.82 - 3.78 (m, 2H), 3.77 - 3.73 (m, 3H), 3.42 (d, J = 4.6 Hz, 2H).</p><p>2-(3-oxo-2-(3-phenylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)isoindoline-1,3-dione (3j)</p><p>Compound 3j was found to be sundown oil, yield 43%. ESI-MS (m/z): 425 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 7.99 (dd, J = 5.5, 3.0 Hz, 1H), 7.83 (dd, J = 5.5, 3.0 Hz, 2H), 7.45 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 7.28 - 7.19 (m, 3H), 4.63 (s, 2H), 3.77 (d, J = 5.9 Hz, 2H), 3.02 (t, J = 7.5 Hz, 2H), 2.80 (t, J = 7.4 Hz, 2H).</p><p>2-(2-nicotinoyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)isoindoline-1,3-dione (3k)</p><p>Compound 6k was found to be reddish brown solid, yield 41%. ESI-MS (m/z): 398 (M + H<sup>+</sup>), m.p. 215˚C - 217˚C. <sup>1</sup>H NMR (400 MHz, Chloroform-d) δ 9.29 (dd, J = 1.8, 0.7 Hz, 1H), 8.84 (dd, J = 3.9, 1.4 Hz, 1H), 8.36 (dt, J = 6.4, 1.6 Hz, 1H), 7.97 (dd, J = 4.4, 2.4 Hz, 2H), 7.82 (dd, J = 4.3, 2.4 Hz, 2H), 7.48 - 7.44 (m, 4H), 4.94 (s, 2H), 3.62 (d, J = 4.7 Hz, 2H).</p></sec><sec id="s3_2"><title>3.2. Bio-Evaluation</title><p>In vitro AChE inhibitory activity screening [<xref ref-type="bibr" rid="scirp.63017-ref6">6</xref>]</p><p>The modified Ellman method was taken in this work to test the AChE inhibitory activity of the synthesized compounds. The enzyme AChE purchased from Sigma Chemical and the positive control donepezil purchased from Dalian Meilun Biotech (China). Meanwhile, 5,5-Dithio-bis(2-nitrobenzoic) acid (DTNB, 0.2 mM) was taken as color agent and acetylthiocholine (0.4 mM) as substrates. All compounds were determined in 100 mM phosphate buffer (pH 8.0) at 30˚C and IC<sub>50</sub> values were calculated through UV spectroscopy based on the absorbance changes at 412 nm. Data are displayed as means&#177;SD depending on three different experiments at least.</p><p>In vitro BACE 1 inhibit activity screening [<xref ref-type="bibr" rid="scirp.63017-ref7">7</xref>]</p><p>The FRET-based enzymatic kits (purchased from Shanghai Haling biological technological CO., LTD., China) were used in this work to test the BACE 1 inhibitory activities of all synthesized compounds. And the assay was carried out by following the manufacturers’ instructions. Meanwhile, the excitation and emission wavelength were set to 340 and 490 nm respectively to evaluate the hydrolysis of substrate. The final data are displayed as means &#177; SD depending on three different experiments at least.</p><p>Hydrogen peroxide scavenging activity assay [<xref ref-type="bibr" rid="scirp.63017-ref8">8</xref>]</p><p>Hydrogen peroxide scavenging activity was determined by a slightly modified version of ferrous ion oxidation-xylenol orange (FOX) assay. Firstly, to prepare the FOX reagent, nine fold volumes of reagent A, 4.4 mM butylated hydroxytoluene (BHT) in methanol, was added to one fold volume of reagent B, 2.56 mM ammonium ferrous sulfate and 1 mM xylenol orange in 250 &#181;M H<sub>2</sub>SO<sub>4</sub>. Secondly, 400 &#181;L of the test compounds with different concentrations were added to 100 μL of 1 mM H<sub>2</sub>O<sub>2</sub> and incubated for 10 h at 37˚C in the dark. And then, 500 &#181;L of the FOX agent was added. Thirdly, the reaction mixture was shaken and incubated for 30 min at room temperature. The appearing of a violet color in the back of the addition of the FOX agent presents a positive control reaction. On the contrary, discoloration is linked to scavenging activity. Lastly, to determine the absorbance of the mixture, the complex was evaluated at 560 nm. Notable, the FOX reagent with H<sub>2</sub>O<sub>2</sub> acted as a control, while the FOX reagent lacking of compound and H<sub>2</sub>O<sub>2</sub> acted as a blank.</p><p>Cytotoxicity assay [<xref ref-type="bibr" rid="scirp.63017-ref9">9</xref>]</p><p>The Human Embryonic Kidney 293 cells (HEK293) were taken in this test and cultured with the DMEM medium in a humidified environment at 37˚C with 5% CO<sub>2</sub>. The media was supplemented with 100 units/ml penicillin, 10% fetal bovine serum (FBS) and 100 units/ml streptomycin. Cells were sub-cultured and grown in collagen-coated tissue culture flasks. The cells were taken for the assay when they become 70% confluent. The compound cytotoxicity was reflected by measuring the cells’ ability to reduce WST-8 to WST-8 formazan. The cells were seeded into 96-well culture plate with proper concentration (5 &#215; 10<sup>3</sup>) at their exponential growth phase, then incubated in a CO<sub>2</sub> incubator overnight. Next, 5 &#181;L compounds (1, 10, 50, 100 and 200 &#181;M in final concentration) were added to each well of the plate and incubated for another 4 h. Then, 10 &#181;L WSK-8 (at final concentration 0.3 mg/ml in DMEM without phenol red) was added to each well and incubated for another 2 h. At last, the absorbance values of each well were obtained by a microplate reader at 450 nm. Cells without the test compounds acted as positive control and its assay values were set to 100%. The test compounds were dissolved in DMSO at 10 mM concentration firstly and then diluted to above-mentioned concentration in 10 mM phosphate buffer pH 7.4. Data of this test was recorded depending on three independent experiments and values of each well were read in triplicate.</p></sec></sec><sec id="s4"><title>4. Conclusion</title><p>In this work, 3 series of new compounds have been designed, synthesized and biologically evaluated as multifunctional agents able to inhibit BACE 1 and AChE enzymes, using the scaffolds of (+)-(S)-dihydro-ar-tume- rone and (−)-gallocatechin gallate as references for lead-optimization aiming to find new molecules for further in vivo preclinical researches targeted Alzheimer’s disease. As shown in <xref ref-type="table" rid="table1">Table 1</xref>, the potent BACE 1 and AChE inhibiting activity for almost half of the synthesized compounds confirmed the reasonability of the new molecular skeleton, tetrahydroisoquinolin-3-one we proposed. Meanwhile, some of these compounds exhibited hydrogen peroxide scavenging activity, which indicated that our synthesized compounds might also release the progress of neurodegenerative disorders by clearing the reactive oxygen species (ROS). In addition, the cytotoxicity assay of compound 1d, 2e, 2j, 3d and 3f showed low cell toxicity to HEK 293 cells in vitro. Altogether, the initial expectations of this research have been fulfilled, and a new, easily synthesized molecular skeleton, tetrahydroisoquinolin-3-one targeting to BACE 1 and AChE has been discovered. Compound 3d, one of its derivates, with potent BACE 1 and AChE inhibition, as well as hydrogen peroxide scavenging activity and low cell toxicity, might be considered as a promising anti-AD candidate for further research.</p></sec><sec id="s5"><title>Acknowledgements</title><p>The financial support from the National Natural Science Foundation of China (No. 20876180) is gratefully acknowledged. The authors also would like to thank School of Pharmaceutical Sciences of Central South University for support of MOE and microplate reader for this research project.</p></sec><sec id="s6"><title>Cite this paper</title><p>YouchaoDeng,YurenJiang,XiongjieZhao,JinlianWang, (2016) Design, Synthesize and Bio-Evaluate 1,2-Dihydroisoquinolin-3(4H)-One Derivates as Acetylcholinesterase and β-Secretase Dual Inhibitors in Treatment with Alzheimer’s Disease. Journal of Biosciences and Medicines,04,112-123. doi: 10.4236/jbm.2016.41014</p></sec><sec id="s7"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.63017-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E.M. (1984) Clinical Diagnosis of Alzheimer’s Disease Report of the NINCDS-ADRDA Work Group* under the Auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34, 939-939. http://dx.doi.org/10.1212/WNL.34.7.939</mixed-citation></ref><ref id="scirp.63017-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Guzior, N., Wieckowska, A., Panek, D. and Malawska, B. (2015) Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease. Current Medicinal Chemistry, 22, 373-404.http://dx.doi.org/10.2174/0929867321666141106122628</mixed-citation></ref><ref id="scirp.63017-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Melchiorre, C., Bolognesi, M.L., Minarini, A., Rosini, M. and Tumiatti, V. (2010) Polyamines in Drug Discovery: From the Universal Template Approach to the Multitarget-Directed Ligand Design Strategy. Journal of Medicinal Chemistry, 53, 5906-5914. http://dx.doi.org/10.1021/jm100293f</mixed-citation></ref><ref id="scirp.63017-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Jeon, S.-Y., Bae, K., Seong, Y.-H. and Song, K.-S. (2003) Green Tea Catechins as a BACE1 (β-Secretase) Inhibitor. Bioorganic &amp; Medicinal Chemistry Letters, 13, 3905-3908. http://dx.doi.org/10.1016/j.bmcl.2003.09.018</mixed-citation></ref><ref id="scirp.63017-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Shimmyo, Y., Kihara, T., Akaike, A., Niidome, T. and Sugimoto, H. (2008) Epigallocatechin-3-Gallate and Curcumin Suppress Amyloid Beta-Induced Beta-Site APP Cleaving Enzyme-1 Upregulation. Neuroreport, 19, 1329-1333.http://dx.doi.org/10.1097/WNR.0b013e32830b8ae1</mixed-citation></ref><ref id="scirp.63017-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ellman, G.L., Courtney, K.D., Andres, V. and Featherstone, R.M. (1961) A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity. Biochemical Pharmacology, 7, 88-95. http://dx.doi.org/10.1016/0006-2952(61)90145-9</mixed-citation></ref><ref id="scirp.63017-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Huang, W., Tang, L., Shi, Y., Huang, S., Xu, L., Sheng, R., Wu, P., Li, J., Zhou, N. and Hu, Y. (2011) Searching for the Multi-Target-Directed Ligands against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H 3 R and BACE 1 Inhibitory Activities. Bioorganic &amp; Medicinal Chemistry, 19, 7158-7167.http://dx.doi.org/10.1016/j.bmc.2011.09.061</mixed-citation></ref><ref id="scirp.63017-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Luo, Z., Liang, L., Sheng, J., Pang, Y., Li, J., Huang, L. and Li, X. (2014) Synthesis and Biological Evaluation of a New Series of Ebselen Derivatives as Glutathione Peroxidase (GPx) Mimics and Cholinesterase Inhibitors against Alzheimer’s Disease. Bioorganic &amp; Medicinal Chemistry, 22, 1355-1361. http://dx.doi.org/10.1016/j.bmc.2013.12.066</mixed-citation></ref><ref id="scirp.63017-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Liu, P., Niu, Y., Wang, C., Sun, Q., Zhai, Y., Yu, J., Sun, J., Xu, F., Yan, G. and Huang, W. (2014) 4-Oxo-1, 4-Dihydro-Quinoline-3-Carboxamides as BACE-1 Inhibitors: Synthesis, Biological Evaluation and Docking Studies. European Journal of Medicinal Chemistry, 79, 413-421. http://dx.doi.org/10.1016/j.ejmech.2014.04.025</mixed-citation></ref><ref id="scirp.63017-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Rahmani, S., Mohammadi, R. and Entezami, A.A. (2008) In Comparison of Syndiotactic Polystyrene Morphology Obtained via Heterogeneous and Homogeneous Polymerization with Metallocene Catalyst, Macromolecular Symposia. Wiley Online Library, 43-48.</mixed-citation></ref><ref id="scirp.63017-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Barlas, H., Kotzias, D. and Parlar, H. (1985) Photo Reactions of Nitrogen Dioxide and Indane in Solution. Chemosphere, 14, 1231-1238. http://dx.doi.org/10.1016/0045-6535(85)90144-4</mixed-citation></ref><ref id="scirp.63017-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Shi, S.-L., Wei, X.-F., Shimizu, Y. and Kanai, M. (2012) Copper (I)-Catalyzed Enantioselective Incorporation of Ketones to Cyclic Hemiaminals for the Synthesis of Versatile Alkaloid Precursors. Journal of the American Chemical Society, 134, 17019-17022. http://dx.doi.org/10.1021/ja308872z</mixed-citation></ref><ref id="scirp.63017-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Meese, C.O. and Ebner, T. (1988) Synthesis of Deuterated 1, 2, 3, 4-Tetrahydroisoquinolines. Journal of Labelled Compounds and Radiopharmaceuticals, 25, 335-343. http://dx.doi.org/10.1002/jlcr.2580250313</mixed-citation></ref><ref id="scirp.63017-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Nevy, J.B., Hawkinson, D.C., Blotny, G., Yao, X. and Pollack, R.M. (1997) Transition State Imbalance in the Deprotonation of Substituted 2-Tetralones by Hydroxide Ion. Journal of the American Chemical Society, 119, 12722-12726.http://dx.doi.org/10.1021/ja972600c</mixed-citation></ref><ref id="scirp.63017-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Z.J., Wang, L.M., Zou, G., Zhang, L., Zhang, G.J., Cai, X.F. and Teng, M.S. (2012) Colorimetric and Ratiometric Fluorescent Chemosensor for Fluoride Ion Based on Perylene Diimide Derivatives. Dyes and Pigments, 94, 410-415. http://dx.doi.org/10.1016/j.dyepig.2012.01.024</mixed-citation></ref><ref id="scirp.63017-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Snow, R.J., Cardozo, M.G., Morwick, T.M., Busacca, C.A., Dong, Y., Eckner, R.J., Jacober, S., Jakes, S., Kapadia, S. and Lukas, S. (2002) Discovery of 2-Phenylamino-Imidazo [4, 5-h] Isoquinolin-9-Ones: A New Class of Inhibitors of Lck Kinase. Journal of Medicinal Chemistry, 45, 3394-3405. http://dx.doi.org/10.1021/jm020113o</mixed-citation></ref><ref id="scirp.63017-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Koszelewski, D., Cwiklak, M. and Ostaszewski, R. (2012) A New Chemoenzymatic Approach to the Synthesis of Chiral 4-Aryl-1, 4-Dihydro-2H-Isoquinolines via the Enzymatic Resolution of 2-Acetyl-4-Phenyl-1, 4-Dihydro-2H- Isoquinolin-3-One. Tetrahedron: Asymmetry, 23, 1256-1261. http://dx.doi.org/10.1016/j.tetasy.2012.07.013</mixed-citation></ref></ref-list></back></article>